BMO Capital Maintains Outperform on Macrogenics, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout has maintained an Outperform rating on Macrogenics (NASDAQ:MGNX) and increased the price target from $18 to $24.
March 08, 2024 | 4:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has reaffirmed its Outperform rating on Macrogenics and raised the price target from $18 to $24.
The increase in price target by BMO Capital suggests a positive outlook on Macrogenics' stock, likely due to favorable analysis or expected performance improvements. This endorsement from a reputable analyst could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100